Bayer announced today that the FINEARTS-HF trial met its primary endpoint by achieving a statistically significant reduction in the composite of cardiovascular death and total (first and recurrent) heart failure…
The “U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report” for 2024-2030 has been added to ResearchAndMarkets.com’s portfolio. This report forecasts that the U.S. oligonucleotide synthesis market will reach…
bioAffinity Technologies today announced agreements with three accredited investors to exercise outstanding warrants, totaling 1,041,667 shares of common stock, for gross proceeds of approximately $1,302,083. In exchange, the investors will…
Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for AMX0035, its proprietary combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO) for treating Wolfram syndrome. This designation follows…
OS Therapies Announces Formation of Osteosarcoma Patient Advocacy Advisory Board OS Therapies, a biopharmaceutical company specializing in cancer immunotherapy and Antibody Drug Conjugates (ADCs), has announced the establishment of a…
Coya Therapeutics, a clinical-stage biotechnology firm specializing in biologics to enhance regulatory T cell (Treg) function, will present data from its phase 2, double-blind, placebo-controlled study of interleukin-2 (IL-2) for…
Agilent has announced that it has received FDA approval for the MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for…
Puma Biotechnology, a biopharmaceutical company, has released its financial results for the second quarter ending June 30, 2024. Comparisons are made between Q2 2024 and Q2 2023, unless specified otherwise.…
Neurocrine Biosciences today announced its financial results for the second quarter ending June 30, 2024, and provided an update on its 2024 financial outlook. Dr. Kevin Gorman, Chief Executive Officer…
Labcorp reported strong revenue and EPS growth for the second quarter of 2024, reflecting significant momentum as the company progresses into the latter half of the year. Chairman and CEO…
Today, a groundbreaking environmental health impact initiative was announced to assist those most vulnerable to extreme weather events, which can exacerbate existing chronic conditions. Initially, the initiative will focus on…
Vertex Announces Q2 2024 Financial Results, Raises Full-Year Product Revenue Guidance Vertex today reported consolidated financial results for the second quarter ending June 30, 2024, and increased its full-year product…